You are here

PD-L1

Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-partnered I/O drug

Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-partnered I/O drug

Endpoints

immuno-oncology

Flag link:

Padding its lung cancer lead, Merck's Keytruda helped PD-L1 patients live 30 months longer

Padding its lung cancer lead, Merck's Keytruda helped PD-L1 patients live 30 months longer

Fierce Pharma

Flag link:

Bristol-Myers' Opdivo fails key lung cancer study, stocks ricochet

Bristol-Myers' Opdivo fails key lung cancer study, stocks ricochet

BioPharma Dive

Bristol-Myers Squibb

non-small cell lung cancer

Flag link:

Merck KGaA/Pfizer analysis of PD-L1 drug for rare skin cancer shows encouraging interim results

Merck KGaA/Pfizer analysis of PD-L1 drug for rare skin cancer shows encouraging interim results

BioPharma Dive

Merkel cell carcinoma

Flag link:

Roche, Kite Pharma sign CAR-T and PD-L1 combo deal

Roche, Kite Pharma sign CAR-T and PD-L1 combo deal

Fierce Biotech

Flag link:

Roche's new PD-L1 bladder cancer drug could be on the market by September

Roche's new PD-L1 bladder cancer drug could be on the market by September

Fierce Biotech

Flag link:

Roche adds another positive snapshot for its PD-L1 checkpoint star 'atezo'

Roche adds another positive snapshot for its PD-L1 checkpoint star 'atezo'

Fierce Biotech

triple negative breast cancer

Flag link:

Roche hustles to FDA with PhII PD-L1 cancer success for 'breakthrough' star atezo

Roche hustles to FDA with PhII PD-L1 cancer success for 'breakthrough' star atezo

Fierce Biotech

Flag link:

Roche's new round of lung cancer data keeps spotlight on immunotherapies

Roche's new round of lung cancer data keeps spotlight on immunotherapies

Fierce Biotech

non-small cell lung cancer

Flag link:

Bristol Myers Squibb And The New Wave Of Cancer Drugs

Bristol Myers Squibb And The New Wave Of Cancer Drugs

Seeking Alpha

Bristol-Myers Squibb

Flag link: